Biotech company.
1 AI-extracted insight from 1 source — podcasts, YouTube channels, and X/Twitter accounts.
Not enough scored insights about Monopar Therapeutics Inc. in the last 30 days yet.
The 1 sources with the most insights about Monopar Therapeutics Inc. on Kazuha.
AI-generated insights from podcasts, YouTube videos, and X posts — ordered by most recent.
The speaker is bearish, stating the company's main drug is 'garbage' and considers the stock a 'shorter'.
The speaker is bearish, stating the company's main drug is 'garbage' and considers the stock a 'shorter'.
Other assets that creators frequently mention in the same content as Monopar Therapeutics Inc..
The most active sources covering Monopar Therapeutics Inc. (MNPR) on Kazuha are @realmartinshkreli. Kazuha aggregates AI-extracted insights from podcasts, YouTube channels, and X/Twitter accounts.
Kazuha has indexed 1 AI-extracted insight about Monopar Therapeutics Inc. (MNPR) from 1 different source. New insights are added whenever a covered creator publishes a new podcast episode, video, or post.
Creators covering Monopar Therapeutics Inc. (MNPR) most frequently also discuss RGTI, QUBT, IONQ, ANAB, JNJ. See the "Discussed alongside" section above for full asset pages.